awmsg logo



dalbavancin (Xydalba®)


Reference No. 2001

Publication date:
25/07/2018


Appraisal information

dalbavancin (Xydalba®) 500 mg powder for concentrate for solution for infusion


Company: Cardiome UK Ltd
BNF category: Infections
NMG meeting date: 13/06/2018
AWMSG meeting date: 18/07/2018
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 1118
Ratification by Welsh Government: 23/07/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Dalbavancin (Xydalba®) is recommended as an option for restricted use within NHS Wales. Dalbavancin (Xydalba®) should be restricted for use in the following circumstances within its licensed indication for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults: • as a second-line treatment of ABSSSI; or • when methicillin-resistant Staphylococcus aureus (MRSA) infection is suspected; or • on the advice of local microbiologists or infectious disease specialists; and • the patient is at first hospitalised due to ABSSSI and needs intravenous antibiotics but is allowed early discharge as they don’t need further inpatient treatment. Dalbavancin (Xydalba®) is not recommended for use within NHS Wales outside of these circumstances.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download